ePrints

Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)

Lookup NU author(s): Dr Aaron Wetten, Professor David Jones, Dr Jess Dyson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.Introduction: Generic fibrates are used off-label as add-in therapy for the management of primary biliary cholangitis (PBC) but with unproven long-term liver-related survival benefits. The recently developed fibrate, seladelpar, has shown promising results in clinical trials, but these outcomes have been previously marred by safety concerns. Areas covered: We summarize existing treatment options in PBC and evaluate current trial data for seladelpar in relation to liver biochemistry, symptomology, and safety. Expert opinion: Seladelpar leads to marked improvement in liver biochemistry and may improve symptoms. Safety concerns around liver toxicity appear to have been addressed. With likely increasing evidence compared to existing off-label fibrates, seladelpar has the potential as an attractive future second-line agent in PBC.

Publication metadata

Author(s): Wetten A, Jones DEJ, Dyson JK

Publication type: Review

Publication status: Published

Journal: Expert Opinion on Investigational Drugs

Year: 2022

Volume: 31

Issue: 10

Pages: 1101-1107

Online publication date: 04/10/2022

Acceptance date: 27/09/2022

ISSN (print): 1354-3784

ISSN (electronic): 1744-7658

Publisher: Taylor and Francis Ltd.

URL: https://doi.org/10.1080/13543784.2022.2130750

DOI: 10.1080/13543784.2022.2130750

PubMed id: 36194037

Share